Enzo Biochem Ownership
| ENZ Stock | USD 1.08 0.05 4.85% |
Shares in Circulation | First Issued 1985-12-31 | Previous Quarter 51.2 M | Current Value 52.2 M | Avarage Shares Outstanding 32.9 M | Quarterly Volatility 11.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Enzo |
Enzo Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enzo Biochem recorded a loss per share of 0.19. The entity last dividend was issued on the 15th of November 2024. The firm had 105:100 split on the 21st of October 2004. Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is headquartered in Farmingdale, New York. Enzo Biochem operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 465 people. To learn more about Enzo Biochem call Hamid Erfanian at 631 755 5500 or check out https://www.enzo.com.Besides selling stocks to institutional investors, Enzo Biochem also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Enzo Biochem's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Enzo Biochem's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Enzo Biochem Quarterly Liabilities And Stockholders Equity |
|
About 22.0% of Enzo Biochem are currently held by insiders. Unlike Enzo Biochem's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Enzo Biochem's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Enzo Biochem's insider trades
Enzo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enzo Biochem is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enzo Biochem backward and forwards among themselves. Enzo Biochem's institutional investor refers to the entity that pools money to purchase Enzo Biochem's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bbr Partners, Llc | 2024-09-30 | 100 K | Nierenberg Investment Management Co | 2024-09-30 | 88.6 K | Northern Trust Corp | 2024-09-30 | 67.2 K | Lazard Asset Management Llc | 2024-06-30 | 50.5 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 44.8 K | Xtx Topco Ltd | 2024-09-30 | 34.4 K | Citadel Advisors Llc | 2024-09-30 | 26.6 K | Kempner Capital Management Inc | 2024-09-30 | 25.5 K | Millennium Management Llc | 2024-06-30 | 19.4 K | Harbert Fund Advisors Inc | 2024-09-30 | 5.2 M | Renaissance Technologies Corp | 2024-09-30 | 2.5 M |
Enzo Biochem Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enzo Biochem insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enzo Biochem's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enzo Biochem insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enzo Biochem Outstanding Bonds
Enzo Biochem issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Enzo Biochem uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Enzo bonds can be classified according to their maturity, which is the date when Enzo Biochem has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Enzo Stock Analysis
When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.